HDACi has been used in glioma therapeutic studies, and the combination of mTOR inhibitors and HDACi can inhibit the mTOR signaling pathway, thereby suppressing oncogene expression, reducing protein synthesis, leading to cell cycle arrest, and thus affecting tumor cells' HDACi, which has an invasive capacity and has entered clinical phase III trials in metastatic renal cell carcinoma. The gene discussed is MTOR; the disease is central nervous system cancer.